180 related articles for article (PubMed ID: 24816152)
1. Phase I study of olaratumab in Japanese patients with advanced solid tumors.
Doi T; Ma Y; Dontabhaktuni A; Nippgen C; Nippgen J; Ohtsu A
Cancer Sci; 2014 Jul; 105(7):862-9. PubMed ID: 24816152
[TBL] [Abstract][Full Text] [Related]
2. A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumors.
Chiorean EG; Sweeney C; Youssoufian H; Qin A; Dontabhaktuni A; Loizos N; Nippgen J; Amato R
Cancer Chemother Pharmacol; 2014 Mar; 73(3):595-604. PubMed ID: 24452395
[TBL] [Abstract][Full Text] [Related]
3. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors.
Wagner AJ; Kindler H; Gelderblom H; Schöffski P; Bauer S; Hohenberger P; Kopp HG; Lopez-Martin JA; Peeters M; Reichardt P; Qin A; Nippgen J; Ilaria RL; Rutkowski P
Ann Oncol; 2017 Mar; 28(3):541-546. PubMed ID: 28426120
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft-tissue sarcoma.
Yonemori K; Kodaira M; Satoh T; Kudo T; Takahashi S; Nakano K; Ando Y; Shimokata T; Mori J; Inoue K; Oakley GJ; Sakaguchi S; Tamura K
Cancer Sci; 2018 Dec; 109(12):3962-3970. PubMed ID: 30353601
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC-3G3) to patients with advanced soft tissue sarcoma.
Villalobos VM; Mo G; Agulnik M; Pollack SM; Rushing DA; Singh A; Van Tine BA; McNaughton R; Decker RL; Zhang W; Shahir A; Cronier DM
Cancer Med; 2020 Feb; 9(3):882-893. PubMed ID: 31821732
[TBL] [Abstract][Full Text] [Related]
7. Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors.
Gordon MS; Sweeney CS; Mendelson DS; Eckhardt SG; Anderson A; Beaupre DM; Branstetter D; Burgess TL; Coxon A; Deng H; Kaplan-Lefko P; Leitch IM; Oliner KS; Yan L; Zhu M; Gore L
Clin Cancer Res; 2010 Jan; 16(2):699-710. PubMed ID: 20068101
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors.
Mascarenhas L; Ogawa C; Laetsch TW; Weigel BJ; Bishop MW; Krystal J; Borinstein SC; Slotkin EK; Muscal JA; Hingorani P; Levy DE; Mo G; Shahir A; Wright J; DuBois SG
Cancer Med; 2021 Feb; 10(3):843-856. PubMed ID: 33474828
[TBL] [Abstract][Full Text] [Related]
9. Safety, tolerability, and pharmacokinetics of single and multiple doses of intravenous cixutumumab (IMC-A12), an inhibitor of the insulin-like growth factor-I receptor, administered weekly or every 2 weeks in patients with advanced solid tumors.
Higano CS; Berlin J; Gordon M; LoRusso P; Tang S; Dontabhaktuni A; Schwartz JD; Cosaert J; Mehnert JM
Invest New Drugs; 2015 Apr; 33(2):450-62. PubMed ID: 25749986
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of the second-generation, recombinant, human EGFR antibody necitumumab in Japanese patients with advanced solid tumors.
Tamura Y; Nokihara H; Honda K; Tanabe Y; Asahina H; Yamada Y; Enatsu S; Kurek R; Yamamoto N; Tamura T
Cancer Chemother Pharmacol; 2016 Nov; 78(5):995-1002. PubMed ID: 27628194
[TBL] [Abstract][Full Text] [Related]
11. Safety and pharmacokinetics of panitumumab in Japanese patients with advanced solid tumors.
Doi T; Ohtsu A; Tahara M; Tamura T; Shirao K; Yamada Y; Otani S; Yang BB; Ohkura M; Ohtsu T
Int J Clin Oncol; 2009 Aug; 14(4):307-14. PubMed ID: 19705240
[TBL] [Abstract][Full Text] [Related]
12. A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors.
Doi T; Shitara K; Kojima T; Yoshino T; Dontabhaktuni A; Rebscher H; Tang S; Cosaert J; Ohtsu A
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1253-62. PubMed ID: 27139036
[TBL] [Abstract][Full Text] [Related]
13. Olaratumab: A Novel Platelet-Derived Growth Factor Receptor α-Inhibitor for Advanced Soft Tissue Sarcoma.
Andrick BJ; Gandhi A
Ann Pharmacother; 2017 Dec; 51(12):1090-1098. PubMed ID: 28778132
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors.
Keam B; Ock CY; Kim TM; Oh DY; Kang WK; Park YH; Lee J; Lee JH; Ahn YH; Kim HJ; Chang SK; Park J; Choi JY; Song YJ; Park YS
Invest New Drugs; 2021 Dec; 39(6):1624-1632. PubMed ID: 34268711
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer.
Saif MW; Knost JA; Chiorean EG; Kambhampati SR; Yu D; Pytowski B; Qin A; Kauh JS; O'Neil BH
Cancer Chemother Pharmacol; 2016 Oct; 78(4):815-24. PubMed ID: 27566701
[TBL] [Abstract][Full Text] [Related]
16. Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma.
Schöffski P; Bahleda R; Wagner AJ; Burgess MA; Junker N; Chisamore M; Peterson P; Szpurka AM; Ceccarelli M; Tap WD
Clin Cancer Res; 2023 Sep; 29(17):3320-3328. PubMed ID: 37382656
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors.
LoRusso PM; Gounder M; Jalal SI; André V; Kambhampati SRP; Loizos N; Hall J; Holzer TR; Nasir A; Cosaert J; Kauh J; Chiorean EG
Invest New Drugs; 2017 Aug; 35(4):442-450. PubMed ID: 28161886
[TBL] [Abstract][Full Text] [Related]
18. A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors.
Angevin E; Tabernero J; Elez E; Cohen SJ; Bahleda R; van Laethem JL; Ottensmeier C; Lopez-Martin JA; Clive S; Joly F; Ray-Coquard I; Dirix L; Machiels JP; Steven N; Reddy M; Hall B; Puchalski TA; Bandekar R; van de Velde H; Tromp B; Vermeulen J; Kurzrock R
Clin Cancer Res; 2014 Apr; 20(8):2192-204. PubMed ID: 24563479
[TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer.
Mo G; Baldwin JR; Luffer-Atlas D; Ilaria RL; Conti I; Heathman M; Cronier DM
Clin Pharmacokinet; 2018 Mar; 57(3):355-365. PubMed ID: 28620891
[TBL] [Abstract][Full Text] [Related]
20. Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies.
Weiner LM; Belldegrun AS; Crawford J; Tolcher AW; Lockbaum P; Arends RH; Navale L; Amado RG; Schwab G; Figlin RA
Clin Cancer Res; 2008 Jan; 14(2):502-8. PubMed ID: 18223225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]